Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogenic ASCs for Primary Progressive Multiple Sclerosis
NCT06592703Phase 1Recruiting
- Sponsor
- CHU Rennes
- Start
- Mar 2025
- Primary completion
- Dec 2029
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adipose derived mesenchymal stromal cells in primary progressive multiple sclerosis (PPMS), sponsored by CHU Rennes. Primary endpoint: Percentage of patients experiencing at least one adverse effect at 48 weeks. Started Mar 2025; status: recruiting.
02
Drugs
adipose derived mesenchymal stromal cells
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NCT06592703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592703.